Conmed (CNMD) Tops Q4 EPS by 13c ; Offers Guidance

Conmed (NYSE: CNMD) reported Q4 EPS of $1.34, $0.13 better than the analyst estimate of $1.21. Revenue for the quarter came in at $345.9 million versus the consensus estimate of $341 million.

GUIDANCE:

Conmed sees FY2025 EPS of $4.25-$4.40, versus the consensus of $4.03. Conmed sees FY2025 revenue of $1.34-1.37 billion, versus the consensus of $1.3 billion.

For earnings history and earnings-related data on Conmed (CNMD) click here.

You May Also Be Interested In

• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• Guggenheim Reiterates Buy Rating on EyePoint Inc. (EYPT)
• Goldman Sachs closes short THB/INR trade for small gain